Emerging drugs for the treatment of basal cell carcinoma

References

• Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: european consensus–based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
   PubMed Web of Science ®Google Scholar
• Asgari MM, Moffet HH, Ray GT, et al. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol. 2015;151:976.
   PubMed Web of Science ®Google Scholar
• Eshini P, Gnaneswaran N, Staines C, et al. Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. Australas J Dermatol. 2015;56:258–267.
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851.
   PubMed Web of Science ®Google Scholar
• Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–1671.
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152:43–51.
   PubMed Web of Science ®Google Scholar
• Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–2269.
   PubMed Web of Science ®Google Scholar
• Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111:1476–1481.
   PubMed Web of Science ®Google Scholar
• Peris K, Licitra L, Ascierto PA, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol. 2015;11:703–712.
   PubMed Web of Science ®Google Scholar
• Amici JM, Battistella M, Beylot-Barry M, et al. Defining and recognising locally advanced basal cell carcinoma. Eur J Dermatol. 2015;25:586–594.
   PubMed Web of Science ®Google Scholar
• McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774–783.
   PubMed Web of Science ®Google Scholar
• Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348.
   PubMed Web of Science ®Google Scholar
• Herms F, Lambert J, Grob -J-J, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter french study of 116 patients. JCO. 2019;37:3275–3282.
   PubMedGoogle Scholar
• Brinkhuizen T, Reinders MG, van Geel M, et al. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71:1005–1008.
   PubMed Web of Science ®Google Scholar
• Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24:312–329.
   PubMed Web of Science ®Google Scholar
• van Loo E, Mosterd K, Krekels GAM, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10year follow-up. Eur J Cancer. 2014;50:3011–3020.
   PubMed Web of Science ®Google Scholar
• Bozan A, Gode S, Kaya I, et al. Long-term follow-up of positive surgical margins in basal cell carcinoma of the face. Dermatol Surg. 2015;41:761–767.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Ann Inter Med. 2018;169:456.
   PubMed Web of Science ®Google Scholar
• Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016;55:831–844.
   PubMed Web of Science ®Google Scholar
• Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647–654.
   PubMed Web of Science ®Google Scholar
• Roozeboom MH, Arits AHMM, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. Imiquimod vs. Fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136:1568–1574.
   PubMed Web of Science ®Google Scholar
• Jansen MHE, Mosterd K, Arits AHMM, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138:527–533.
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18:547–553.
   PubMed Web of Science ®Google Scholar
• Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30:297–300.
   PubMed Web of Science ®Google Scholar
• Hall VL, Leppard BJ, McGill J, et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37:33–34.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study. Br J Dermatol. 2019;bjd:18552.
   Google Scholar
• Hou X, Rokohl AC, Ortmann M, et al. Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor? Graefes Arch Clin Exp Ophthalmol. 2020;258:2335–2337.
   PubMed Web of Science ®Google Scholar
• Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18:404–412.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Basset‐Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34:1944–1956.
   PubMed Web of Science ®Google Scholar
• Conforti C, Giuffrida R, Di Meo N, et al. Management of locally advanced basal cell carcinoma treated with sonidegib: the experience of an Italian reference hospital. Dermatol Ther [Internet]. 2020. DOI:10.1111/dth.14511
   Web of Science ®Google Scholar
• Peris K, Tambone S, Kostaki D, et al. Treatments of advanced basal cell carcinoma: a review of the literature. G Ital Dermatol Venereol. 2016;151:77–86.
   PubMed Web of Science ®Google Scholar
• Guy GP, Machlin SR, Ekwueme DU, et al. Prevalence and costs of skin cancer treatment in the U.S., 2002−2006 and 2007−2011. Am J Prev Med. 2015;48:183–187.
   PubMed Web of Science ®Google Scholar
• Rogers HW, Coldiron BM. A relative value unit–based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol. 2009;61:96–103.
   PubMed Web of Science ®Google Scholar
• Kish T, Corry L. Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer. P T. 2016;41:322–325.
   PubMedGoogle Scholar
• Jayaraman SS, Rayhan DJ, Hazany S, et al. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol. 2014;134:213–220.
   PubMed Web of Science ®Google Scholar
• Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80:564–566.
   PubMed Web of Science ®Google Scholar
• Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–341.
   PubMed Web of Science ®Google Scholar
• Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–399.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745–751.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell. 2017;170(1109–1119):e10.
   PubMedGoogle Scholar
• Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131:1735–1744.
   PubMed Web of Science ®Google Scholar
• Peluso MO, Campbell VT, Harari JA, et al. Impact of the smoothened inhibitor, IPI-926, on smoothened ciliary localization and hedgehog pathway activity. PLoS One. Syn W-K, editor 2014;9:e90534.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Weiss GJ, Miller WH, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19:2766–2774.
   PubMed Web of Science ®Google Scholar
• Meyer T, Surber C, French LE, et al. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Invest Drugs. 2013;22:149–159.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Hofbauer GFL, Reinhold U, et al. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol [Internet].DOI:10.1111/bjd.17124.
   Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanomA. JCO. 2015;33:2780–2788.
   PubMed Web of Science ®Google Scholar
• Miura JT, Zager JS. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncol. 2019;15:3665–3674.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341–351.
   PubMed Web of Science ®Google Scholar
• Jia H, Liu Y, Xia R, et al. Casein Kinase 2 promotes hedgehog signaling by regulating both smoothened and cubitus interruptus. J Biol Chem. 2010;285:37218–37226.
   PubMed Web of Science ®Google Scholar